Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Fineline Cube Dec 30, 2025
Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Fineline Cube Dec 30, 2025
Company Drug

Tonghua Dongbao’s Tongboli Under GMP Inspection in Egypt

Fineline Cube Mar 4, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced that the on-site Good Manufacturing Practice (GMP) inspection...

Company Drug

United Laboratories’ UBT251 Receives FDA Green Light for Phase II CKD Study

Fineline Cube Mar 4, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) announced that it has received approval...

Company Drug

CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors

Fineline Cube Mar 4, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...

Company Deals

AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal

Fineline Cube Mar 3, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...

Company Medical Device

Zeiss Group’s VISUMAX 800 with SMILE pro Software Approved by China’s NMPA

Fineline Cube Mar 3, 2025

Germany-based Zeiss Group, a specialist in optical systems and optoelectronic product manufacturing, announced that it...

Company Drug

Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials

Fineline Cube Mar 3, 2025

Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...

Company Drug

SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study

Fineline Cube Mar 3, 2025

SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...

Company Deals

Omron Healthcare and China Jo-Jo Drugstores Launch Atrial Fibrillation Screening Zone

Fineline Cube Mar 3, 2025

A joint effort between Japan-based Omron Healthcare and China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), a...

Company Deals

WORK Medical and Chartwell Med Partner on Investment Tools for Healthcare Projects

Fineline Cube Mar 3, 2025

WORK Medical Technology Group Ltd (NASDAQ: WOK), a medical consumables company based in Hangzhou, has...

Company Drug

Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda

Fineline Cube Mar 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...

Deals Drug

Eyebright Medtech Plans Private Placement to Expand Contact Lens Production

Fineline Cube Mar 3, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...

Company Drug

Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment

Fineline Cube Mar 3, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...

Company Deals

Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline

Fineline Cube Mar 3, 2025

Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...

Company Deals

Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics

Fineline Cube Mar 3, 2025

US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...

Company Drug

AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study

Fineline Cube Mar 3, 2025

AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...

Company Deals Digital

Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing

Fineline Cube Mar 3, 2025

Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co.,...

Company Deals

Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules

Fineline Cube Mar 3, 2025

China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...

Company Drug

CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Mar 3, 2025

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...

Company Deals

Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio

Fineline Cube Mar 3, 2025

Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...

Drug

CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment

Fineline Cube Mar 3, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...

Posts pagination

1 … 140 141 142 … 603

Recent updates

  • Broncus Medical Acquires Valgen Stake from Venus for $15 Million
  • CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
  • Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
  • Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.